Drug-testing abbreviations and acronyms

Analyte abbreviations on cassettes and lab reports

Every immunoassay device — whether a single-analyte dip card, a multi-panel cup, or a saliva collection device — labels each test strip with a short alphabetic code identifying the targeted analyte. The same codes appear on most laboratory reports, on chain-of-custody forms, and in panel-configuration sheets when buyers compare devices. The table below covers the analytes most commonly found on workplace, clinical, and treatment-program panels in the United States.

Cutoff concentrations associated with each code follow SAMHSA Mandatory Guidelines for the five federally regulated analytes (THC, COC, AMP, OPI, PCP) and follow manufacturer- or program-defined cutoffs for everything else. The code on the cassette identifies what is being detected; the cutoff determines the threshold at which a result is flagged presumptive positive.

Methodology and procedure acronyms

The second category of abbreviations program buyers encounter describes how a sample is collected, screened, confirmed, and reported. These acronyms appear throughout SAMHSA Mandatory Guidelines, 49 CFR Part 40, laboratory reports, and chain-of-custody forms. Understanding them is essential for procurement conversations with laboratories and for defensible policy language.

The split between screening (immunoassay-based, presumptive) and confirmation (mass-spectrometry-based, definitive) is the most important methodological distinction. A positive immunoassay screen alone is not a confirmed positive, and adverse action should not rest on screening alone in any defensible program.

Regulatory and agency references

Workplace and clinical drug-testing programs sit at the intersection of multiple federal regulatory authorities. The acronyms below identify the agencies, modal administrations, and rule citations program buyers will encounter in SOPs, policy documents, and contract language. For DOT-regulated employers, the modal-administration acronym (FMCSA, FAA, FRA, FTA, PHMSA, USCG) identifies which industry-specific rule applies on top of the common 49 CFR Part 40 procedures.

Programs that do not fall under any of these regimes still encounter the acronyms in adjacent contexts — OSHA recordkeeping for post-accident testing, ADA obligations on prescription-medication review, DEA scheduling references on controlled-substance positives, and FDA-cleared status on the test devices themselves.

Business and procurement terms

Program buyers — particularly those purchasing in volume for clinics, treatment programs, employer programs, or distributor channels — encounter a distinct vocabulary of B2B procurement and documentation terms. These are not testing-specific but appear constantly in quotes, contracts, and shipping documentation. The table below covers the terms most relevant to bulk drug-test ordering.

Programs purchasing on terms (NET 30, NET 60) rather than card-on-file should expect a credit-application step, an established billing relationship, and itemized invoices that include lot numbers and certificates of analysis for the devices shipped. Programs purchasing CLIA-waived devices for on-site testing should also retain the device package insert and the corresponding clearance reference as part of the program file.

How to read a drug-test result

A typical immunoassay cassette result shows a control line (C) and one test line per analyte (labeled with the codes above). The control line confirms the device ran correctly; absence of the control line invalidates the result regardless of any test-line appearance. For each analyte, a visible test line indicates that the analyte concentration is below the cutoff — a negative result. A faint or absent test line, combined with a visible control line, indicates that the analyte concentration is at or above the cutoff — a presumptive positive that should be sent for laboratory confirmation.

A laboratory report adds quantitative detail. The report identifies each analyte tested, the cutoff applied, the screening result, and — for any presumptive positive — the confirmation methodology (typically GC-MS or LC-MS/MS) and the quantitative result. A confirmed positive in a regulated program is then reviewed by the MRO, who contacts the donor, evaluates any legitimate-medical-explanation defense, and issues a final verified result to the DER.

Specimen-validity flags appear separately on the report and identify any indication that the sample was adulterated, diluted, or substituted. Common SVT flags include low creatinine (dilute), abnormal pH (adulterated), abnormal specific gravity (dilute or substituted), and the presence of oxidants or other adulterant chemistries. SVT flags do not by themselves constitute a positive drug result but are reported alongside the analyte results for the MRO and program administrator to consider.

Program buyers comparing devices and laboratories should request the IFU and a sample report from each candidate vendor. The IFU identifies the analytes detected, the cutoffs applied, validated cross-reactivities, and any specimen-handling requirements. The sample report shows how the laboratory will present results to the MRO and to the program — a detail that matters when the program is integrating results into an HRIS, an electronic medical record, or a case-management system.